Effect of empagliflozin combined with benazepril in the treatment of early diabetes kidney disease and its influences on inflammatory response and renal fibrosis indexes
Objective To explore the effect of empagliflozin combined with benazepril in the treatment of early diabetes kidney disease and its influences on inflammatory response and renal fibrosis indexes.Methods A total of 150 patients with early diabetes kidney disease admitted from February 2021 to February 2022 were selected as the research objects,and randomly divided into control group and observation group,with 75 cases in each group.The control group was treated with conventional treatment combined with benazepril,and the observation group was treated with empagliflozin on the basis of the control group.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in the levels of interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)and monocyte chemoattractant protein-1(MCP-1)between the two groups(P>0.05);after treatment,the levels of IL-6,TNF-α and MCP-1 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in the levels of cystatin C(Cys C),tissue inhibitor of metalloproteinase-1(TIMP-1),transforming growth factor-β1(TGF-β1)and collagen type Ⅲ(CⅢ)between the two groups(P>0.05);after treatment,the levels of Cys C,TIMP-1,TGF-β1 and CⅢ in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusion Empagliflozin combined with benazepril has significant effect in the treatment of early diabetes kidney disease,which can effectively regulate the inflammatory reaction of the body,inhibit renal fibrosis,and delay the progress of the disease.
维普
万方数据
